Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics.
C EfstathiouS H AbidiJ HarkerNigel J StevensonPublished in: Cellular and molecular life sciences : CMLS (2020)
Every year there are > 33 million cases of Respiratory Syncytial Virus (RSV)-related respiratory infection in children under the age of five, making RSV the leading cause of lower respiratory tract infection (LRTI) in infants. RSV is a global infection, but 99% of related mortality is in low/middle-income countries. Unbelievably, 62 years after its identification, there remains no effective treatment nor vaccine for this deadly virus, leaving infants, elderly and immunocompromised patients at high risk. The success of all pathogens depends on their ability to evade and modulate the host immune response. RSV has a complex and intricate relationship with our immune systems, but a clearer understanding of these interactions is essential in the development of effective medicines. Therefore, in a bid to update and focus our research community's understanding of RSV's interaction with immune defences, this review aims to discuss how our current knowledgebase could be used to combat this global viral threat.
Keyphrases
- respiratory syncytial virus
- respiratory tract
- immune response
- end stage renal disease
- mental health
- newly diagnosed
- ejection fraction
- young adults
- cardiovascular events
- peritoneal dialysis
- small molecule
- physical activity
- dendritic cells
- inflammatory response
- toll like receptor
- multidrug resistant
- gram negative
- patient reported outcomes
- drug induced
- extracorporeal membrane oxygenation